Allos Therapeutics Inc. picked up $50 million in up-front cash in a much-anticipated ex-U.S. deal for peripheral T-cell lymphoma (PTCL) drug Folotyn (pralatrexate) and hopes the co-development and commercialization muscle of Mundipharma International Corp. Ltd. will help Folotyn capture a large portion of second-line PTCL market outside the U.S., estimated at about $400 million.